コンパニオン診断の世界市場

◆英語タイトル:Companion Diagnostics - Global Market Outlook (2015-2022)
◆商品コード:SMRC65053
◆発行会社(調査会社):Stratistics MRC
◆発行日:2016年3月
◆ページ数:122
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥460,650見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥582,750見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。Stratistics MRC社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、コンパニオン診断の世界市場について調査・分析し、市場動向、市場規模、市場予測、企業動向などを含め、以下の構成でお届けいたします。

・エグゼクティブサマリー
・序文
・市場動向分析
・ファイブフォース分析(市場環境分析)
・コンパニオン診断の世界市場:技術別分析/市場規模
・コンパニオン診断の世界市場:用途別分析/市場規模
・コンパニオン診断の世界市場:疾患別分析/市場規模
・コンパニオン診断の世界市場:需要先別分析/市場規模
・コンパニオン診断の世界市場:地域別分析/市場規模
・コンパニオン診断のアメリカ市場規模予測
・コンパニオン診断のヨーロッパ市場規模予測
・コンパニオン診断のアジア市場規模予測
・企業動向
・企業分析
【レポートの概要】

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $2.62 billion in 2015 and is expected to reach $9.27 billion by 2022 growing at a CAGR of 19.78% during the forecast period. At present, increasing demand for personalized medicine is mostly contributing to the global companion diagnostics market growth. On the other hand, cost allied with developing drugs could hamper the market. Developing companion diagnostics for several central nervous system conditions and hereditary conditions provide ample of opportunities for players in the market.In terms of revenue, Breast cancer commanded the global companion diagnostics market. However, lung cancer is expected to lead the market in future growing at a significant CAGR owing to the discovery of biomarkers that are precise to lung cancer, and the discovery of myriad pertinent companion diagnostics. Molecular diagnostics is highest revenue generating segment and also expected to grow at a faster rate, mainly owing to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing.
North America represented the largest market for companion diagnostics, followed by the Europe. The Asia Pacific and Rest of the World regions are anticipated to witness substantial demand for companion diagnostics in the future. In these regions, enhancing healthcare infrastructure, rising disposable incomes, and unexploited potential for companion diagnostics are cited as the major reasons for the market growth.
Some of the key players in the market include are Roche Diagnostics, Quest Diagnostics Inc.Qiagen N.V., Labcorp, Genomic Health Inc., Dako (Agilent Technologies), Celera, Biomerieux Sa, Abbott Laboratories, Thermo Fisher Scientific, Inc., Danaher Corporation, GE Healthcare, Biogenex Laboratories, Siemens and AstraZeneca.
Technologies Covered:
• Molecular diagnostics
• In Situ Hybridization (ISH)
o CISH
o FISH
• Polymerase Chain Reaction (PCR)
• Next generation sequencing
• Other Technologies
• Immunohistochemistry
Applications Covered:
• Colorectal Cancer
• Gastric Cancer
• Lung Cancer
• Breast Cancer
• Melanoma
• Other Applications
Indications Covered:
• Cardiovascular conditions
• Inflammation
• Virology
• Oncology
• Other Indications
End User’s Covered:
• Pharmaceutical Companies
• Reference Lab
• Physicians
• Hospitals
• Academic Medical Centers
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Companion Diagnostics Market, By Technology
5.1 Introduction
5.2 Molecular diagnostics
5.2.1 In Situ Hybridization (ISH)
5.2.1.1 CISH
5.2.1.1.2 FISH
5.2.2 Polymerase Chain Reaction (PCR)
5.2.3 Next generation sequencing
5.2.4 Other Technologies
5.3 Immunohistochemistry

6 Global Companion Diagnostics Market, By Application
6.1 Introduction
6.2 Colorectal Cancer
6.3 Gastric Cancer
6.4 Lung Cancer
6.5 Breast Cancer
6.6 Melanoma
6.7 Other Applications

7 Global Companion Diagnostics Market, By Indication
7.1 Introduction
7.2 Cardiovascular conditions
7.3 Inflammation
7.4 Virology
7.5 Oncology
7.6 Other Indications

8 Global Companion Diagnostics Market, By End User
8.1 Introduction
8.2 Pharmaceutical Companies
8.3 Reference Lab
8.4 Physicians
8.5 Hospitals
8.6 Academic Medical Centers

9 Global Companion Diagnostics Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Roche Diagnostics
11.2 Quest Diagnostics Inc.
11.3 Qiagen N.V.
11.4 Labcorp
11.5 Genomic Health Inc.
11.6 Dako (Agilent Technologies)
11.7 Celera
11.8 Biomerieux Sa
11.9 Abbott Laboratories
11.10 Thermo Fisher Scientific, Inc.
11.11 Danaher Corporation
11.12 GE Healthcare
11.13 Biogenex Laboratories
11.14 Siemens
11.15 AstraZeneca

List of Tables
Table 1 Global Companion Diagnostics Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
Table 3 Global Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
Table 4 Global Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
Table 5 Global Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
Table 6 Global Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
Table 7 Global Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
Table 8 Global Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
Table 9 Global Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
Table 10 Global Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 11 Global Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
Table 12 Global Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 13 Global Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 14 Global Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
Table 15 Global Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
Table 16 Global Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
Table 17 Global Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
Table 18 Global Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
Table 19 Global Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
Table 20 Global Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
Table 21 Global Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
Table 22 Global Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
Table 23 Global Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
Table 24 Global Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
Table 25 Global Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
Table 26 Global Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
Table 27 Global Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
Table 28 North America Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
Table 29 North America Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
Table 30 North America Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
Table 31 North America Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
Table 32 North America Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
Table 33 North America Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
Table 34 North America Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
Table 35 North America Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
Table 36 North America Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 37 North America Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
Table 38 North America Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 39 North America Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 40 North America Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
Table 41 North America Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
Table 42 North America Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
Table 43 North America Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
Table 44 North America Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
Table 45 North America Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
Table 46 North America Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
Table 47 North America Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
Table 48 North America Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
Table 49 North America Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
Table 50 North America Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
Table 51 North America Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
Table 52 North America Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
Table 53 North America Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
Table 54 Europe Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
Table 55 Europe Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
Table 56 Europe Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
Table 57 Europe Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
Table 58 Europe Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
Table 59 Europe Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
Table 60 Europe Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
Table 61 Europe Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
Table 62 Europe Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 63 Europe Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
Table 64 Europe Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 65 Europe Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 66 Europe Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
Table 67 Europe Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
Table 68 Europe Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
Table 69 Europe Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
Table 70 Europe Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
Table 71 Europe Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
Table 72 Europe Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
Table 73 Europe Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
Table 74 Europe Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
Table 75 Europe Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
Table 76 Europe Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
Table 77 Europe Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
Table 78 Europe Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
Table 79 Europe Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
Table 80 Asia Pacific Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
Table 81 Asia Pacific Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
Table 82 Asia Pacific Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
Table 83 Asia Pacific Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
Table 84 Asia Pacific Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
Table 85 Asia Pacific Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
Table 86 Asia Pacific Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
Table 87 Asia Pacific Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
Table 88 Asia Pacific Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 89 Asia Pacific Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
Table 90 Asia Pacific Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 91 Asia Pacific Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 92 Asia Pacific Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
Table 93 Asia Pacific Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
Table 94 Asia Pacific Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
Table 95 Asia Pacific Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
Table 96 Asia Pacific Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
Table 97 Asia Pacific Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
Table 98 Asia Pacific Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
Table 99 Asia Pacific Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
Table 100 Asia Pacific Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
Table 101 Asia Pacific Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
Table 102 Asia Pacific Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
Table 103 Asia Pacific Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
Table 104 Asia Pacific Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
Table 105 Asia Pacific Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
Table 106 Rest of the World Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
Table 107 Rest of the World Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
Table 108 Rest of the World Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
Table 109 Rest of the World Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
Table 110 Rest of the World Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
Table 111 Rest of the World Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
Table 112 Rest of the World Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
Table 113 Rest of the World Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
Table 114 Rest of the World Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 115 Rest of the World Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
Table 116 Rest of the World Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 117 Rest of the World Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 118 Rest of the World Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
Table 119 Rest of the World Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
Table 120 Rest of the World Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
Table 121 Rest of the World Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
Table 122 Rest of the World Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
Table 123 Rest of the World Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
Table 124 Rest of the World Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
Table 125 Rest of the World Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
Table 126 Rest of the World Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
Table 127 Rest of the World Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
Table 128 Rest of the World Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
Table 129 Rest of the World Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
Table 130 Rest of the World Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
Table 131 Rest of the World Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)



【レポートのキーワード】

コンパニオン診断、コンパニオン診断薬、分子診断、医療、PCR、NGS、癌診断

★調査レポート[コンパニオン診断の世界市場]販売に関する免責事項
★調査レポート[コンパニオン診断の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆